| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99402 |
|
45,341 |
43,099 |
$2.95M |
| 99401 |
|
63,944 |
60,899 |
$2.94M |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
5,692 |
5,393 |
$2.21M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
37,621 |
35,598 |
$1.68M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
37,594 |
35,583 |
$1.68M |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
50,908 |
48,544 |
$986K |
| 11981 |
|
5,660 |
5,375 |
$837K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
19,342 |
18,405 |
$575K |
| 81025 |
|
59,054 |
55,660 |
$397K |
| 58300 |
|
2,844 |
2,568 |
$242K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
706 |
672 |
$236K |
| J7297 |
Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
711 |
672 |
$128K |
| 11976 |
|
1,418 |
1,377 |
$124K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
4,583 |
2,656 |
$115K |
| J7300 |
Intrauterine copper contraceptive (paragard) |
492 |
446 |
$114K |
| 86592 |
|
14,131 |
13,397 |
$78K |
| 58301 |
|
1,411 |
1,322 |
$71K |
| 87210 |
|
11,744 |
11,066 |
$61K |
| 86803 |
|
3,510 |
3,205 |
$60K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
1,792 |
1,257 |
$19K |
| 11982 |
|
1,299 |
1,219 |
$17K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,504 |
3,953 |
$17K |
| 85018 |
|
3,766 |
3,509 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,824 |
1,256 |
$8K |
| 99215 |
Prolong outpt/office vis |
70 |
66 |
$6K |
| 86703 |
|
227 |
208 |
$3K |
| 86780 |
|
83 |
73 |
$1K |
| 86593 |
|
140 |
116 |
$572.39 |
| 83020 |
|
25 |
24 |
$404.58 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
16 |
16 |
$0.00 |